Keymed Biosciences Announces Interim Results for First Half of 2024
Stapokibart (CM310) (IL-4Rα antibody) Stapokibart (CM310) (IL-4Rα antibody) CMG901/AZD0901 (Claudin 18.2 ADC) CM313 (CD38 antibody) CM326 (TSLP antibody) CM355/ICP-B02 (CD20xCD3 bispecific antibody) CM336 (BCMAxCD3 bispecific antibody) CM350 (GPC3xCD3 bispecific antibody) CM369/ICP-B05 (CCR8 antibody) CM383 (Aβ protofibrils antibody) CM380 (GPRC5DxCD3 bispecific antibody) Financial and Business Highlights View original...
Comunicato Precedente
Comunicato Successivo
CHENGDU, China,
(informazione.news - comunicati stampa - salute e benessere)
Stapokibart (CM310) (IL-4Rα antibody)
CMG901/AZD0901 (Claudin 18.2 ADC)
CM313 (CD38 antibody)
CM326 (TSLP antibody)
CM355/ICP-B02 (CD20xCD3 bispecific antibody)
CM336 (BCMAxCD3 bispecific antibody)
CM350 (GPC3xCD3 bispecific antibody)
CM369/ICP-B05 (CCR8 antibody)
CM383 (Aβ protofibrils antibody)
CM380 (GPRC5DxCD3 bispecific antibody)
Financial and Business Highlights
View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-interim-results-for-first-half-of-2024-302232637.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
;
